Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID

Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID - Characterizing Long COVID Phenotypes Using Physiological and Molecular Studies

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06427512

Enrollment

Registered

2024-05-24

Start date

2022-03-31

Completion date

2025-03-31

Last updated

2024-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

long COVID-19

Brief summary

AIM 1. Characterize cardiovascular phenotypes of long COVID by cardiopulmonary, meta-bolic, and cardiac mechanical/physiological responses to exercise and microvascular vasomotor function. AIM 2. Identify intercellular signaling between immune cells and cardiac cells associated with microvascular phenotypes of long COVID.

Detailed description

As many as 40-60% of patients who recovered from mild or moderate acute COVID have reported what is now called long COVID - multiple, persistent or recurrent symptoms lasting 6-9 months (or longer) following initial illness.1-4 Fatigue, dyspnea, and chest pain are the most common symptoms. Others include palpitations, lightheadedness, and syncope. All these cardiovascular symptoms can be debilitating, resulting in worse quality of life and morbidity.5, 6 Treatment options are limited.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to 74 Years

Inclusion criteria

* Age \> 18, \< 75 yrs * History of lab-confirmed COVID * Symptomatic at \>12 wks post-acute COVID (cases) * Recovered by 8wks post-acute COVID (controls)

Exclusion criteria

* Any history of critical illness * Chronic kidney disease, Stage \>4 * Pre-COVID: HFrEF, CABG, arrhythmia; pulmonary hypertension, pulmonary embolus, interstitial lung disease (ILD), O2 dependence; dementia, stroke, autonomic dysfunction; coagulopathy * Post-COVID: ILD, O2 dependence

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of Microvascular dysfunction	Up to 2.5 years	This is to measure the microvascular dysfunction in patients using Cardiac PET.

Countries

United States

Outcome results